Telix initiates first-in-human study of next-generation prostate cancer therapy candidate TLX-592 Aug. 5, 2021
The University of Washington and the Department of Veterans Affairs patent glycolysis inhibitors Aug. 5, 2021
Enrollment opens in phase I study of LP-168 in relapsed or refractory B-cell malignancies Aug. 5, 2021
U.S. phase II dosing begins with LUT-014 to reduce EGFR inhibitor-induced acneiform lesions Aug. 4, 2021
RSS